"Only essential data were to be collected and, wherever possible, much of the follow-up information was derived from national electronic health records (EHRs)"

"Only essential data were to be collected and, wherever possible, much of the follow-up information was derived from national electronic health records (EHRs)" It reminds me Andy Grove clinical trial proposal [0] In short, if it doesn't kill patients in a small phase I trial, give market authorization. Then follow patients through EHRs for a few years, and if too much of them die then revoke marketing authorization. Derek Lowe writings on the subject are, as always, very interesting [1]. [0] https://www.science.org/doi/full/10.1126/science.1212118 https://www.science.org/doi/full/10.1126/science.1212118 [1] https://www.science.org/content/blog-post/reaction-andy-grove-s-clinical-trial-proposals https://www.science.org/content/blog-post/reaction-andy-grov...